Stockreport

Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset [Seeking Alpha]

Nektar Therapeutics  (NKTR) 
Last nektar therapeutics earnings: 2/27 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nektar.com/investor-relations
PDF first-in-class regulatory T cell stimulator, for autoimmune disorders and chronic inflammatory diseases. The firm has a Street-high price target of $4 (~242% upside ba [Read more]